NasdaqGS:AMRS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. More Details


Snowflake Analysis

High growth potential with weak fundamentals.


Similar Companies

Share Price & News

How has Amyris's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: AMRS's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

19.8%

AMRS

-1.4%

US Chemicals

-2.4%

US Market


1 Year Return

365.2%

AMRS

31.9%

US Chemicals

31.2%

US Market

Return vs Industry: AMRS exceeded the US Chemicals industry which returned 31.9% over the past year.

Return vs Market: AMRS exceeded the US Market which returned 31.2% over the past year.


Shareholder returns

AMRSIndustryMarket
7 Day19.8%-1.4%-2.4%
30 Day70.0%-0.4%-3.0%
90 Day453.8%2.4%3.2%
1 Year365.2%365.2%34.7%31.9%34.1%31.2%
3 Year196.2%196.2%26.8%7.1%48.1%38.6%
5 Year-3.2%-3.2%91.3%52.8%116.5%92.3%

Long-Term Price Volatility Vs. Market

How volatile is Amyris's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amyris undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMRS ($16.56) is trading below our estimate of fair value ($63.56)

Significantly Below Fair Value: AMRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMRS is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.

PE vs Market: AMRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMRS has negative assets, so we can't compare its PB Ratio to the US Chemicals industry average.


Next Steps

Future Growth

How is Amyris forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

74.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AMRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AMRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AMRS's revenue (27.2% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: AMRS's revenue (27.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Amyris performed over the past 5 years?

-19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMRS is currently unprofitable.

Growing Profit Margin: AMRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMRS is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.

Accelerating Growth: Unable to compare AMRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMRS is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-1.4%).


Return on Equity

High ROE: AMRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

  • Explore strong past performing companies in the Materials industry.

Financial Health

How is Amyris's financial position?


Financial Position Analysis

Short Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AMRS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AMRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMRS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AMRS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Amyris's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

John Melo (54 yo)

14.17yrs

Tenure

US$1,306,298

Compensation

Mr. John G. Melo has been the Chief Executive Officer at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led Amyris throug...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.31M) is below average for companies of similar size in the US market ($USD4.96M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Melo
President14.17yrsUS$1.31m0.017%
$ 742.5k
Eduardo Alvarez
Chief Operating Officer3.42yrsUS$665.19k0.096%
$ 4.1m
Kathleen Valiasek
Chief Business Officer1.75yrsUS$588.08kno data
Hermanus Kieftenbeld
Chief Financial Officer1yrno data0%
$ 0
Anthony Hughes
Chief Accounting Officer2.75yrsno data0.010%
$ 424.8k
Peter DeNardo
Senior Director of Investor Relations & Corporate Communicationsno datano datano data
Nicole Kelsey
General Counsel & Secretary3.58yrsUS$1.20m0.023%
$ 1.0m
Christine Ofori
Chief People Officerno datano datano data
Charles Kraft
Senior Vice President of Global Manufacturing & Process Development5.5yrsno datano data
Caroline Hadfield
President of Aprinnova5.75yrsno datano data
Jim Iacoponi
Senior Vice President of Nutrition Ingredientsno datano datano data
Beth Baker Bannerman
Chief Engagement & Sustainability Officerno datano datano data

3.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: AMRS's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Melo
President14.17yrsUS$1.31m0.017%
$ 742.5k
Frank F. Kung
Independent Director3.33yrsUS$58.13k0%
$ 0
L. Doerr
Independent Director14.83yrsUS$67.13k28.65%
$ 1.2b
James McCann
Independent Director1.83yrsUS$47.72k0.00020%
$ 8.5k
Steven Mills
Independent Director2.58yrsUS$70.63k0.0051%
$ 219.5k
Geoffrey Duyk
Interim Independent Chair of the Board6.83yrsUS$92.86k0.0017%
$ 74.3k
Carole Piwnica
Independent Director11.5yrsUS$72.63k0.0023%
$ 96.5k
Patrick Yang
Independent Director6.67yrsUS$63.13k0.017%
$ 719.0k
Christoph Goppelsroeder
Director3.33yrsUS$40.00kno data
Julie Washington
Independent Director0.58yrno datano data
Philip Eykerman
Director3.83yrsUS$58.13k0.0022%
$ 93.9k
Lisa Qi
Independent Director1.83yrsUS$25.28kno data

3.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: AMRS's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.1%.


Top Shareholders

Company Information

Amyris, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amyris, Inc.
  • Ticker: AMRS
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: US$4.270b
  • Shares outstanding: 244.95m
  • Website: https://www.amyris.com

Number of Employees


Location

  • Amyris, Inc.
  • 5885 Hollis Street
  • Suite 100
  • EmeryVille
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMRSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2010
3A01DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2010

Biography

Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company’s technology platform e...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/04 23:42
End of Day Share Price2021/03/04 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.